Skip to content
Search

Latest Stories

Former pharmacy minister Steve Brine MP elected as chair of Health and Social Care Committee

Former pharmacy minister Steve Brine was on Wednesday (November 2) elected chair of the influential Health and Social Care Committee, the cross-party parliamentary group that scrutinizes the work of the Department of Health and Social Care and its associated public bodies.

The Conservative MP for Winchester won 253 out of 432 votes beating off four other contenders for the role -- Stephen Hammond, Dr Caroline Johnson, Anne Marie Morris and James Morris -- in a four-stage election in which MPs voted by ranking candidates in order of preference. Dr Johnson, who was Mr Brine's main challenger, bagged 148 votes in the  final round.


An election for a new chair of the Health and Social Care Committee was triggered following the resignation of Jeremy Hunt MP who was appointment as chancellor of the exchequer on October 14.

Issuing a statement after his election, Mr Brine said: “I welcome the opportunity as chair to continue the calm, measured work of Jeremy Hunt and to examine new solutions to support the NHS to enable it to continue providing the services that we all depend upon."

“Despite spending vast sums on health, we fail to reap the rewards in better outcomes. We need to understand why and to press the government about getting better value for our money," he added.

Mr Brine was appointed minister for public health and primary care in 2017 but resigned from his post after 20 months over the government's handling of Brexit.

He has been parliamentary under secretary of state for Health since 2015 and was previously assistant government whip.

Before joining active politics, Mr Brine was a radio journalist with the BBC.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less